Enzyme linked immunosorbent assay market

Q: Which is the leading vaccine segment in the market?

Direct ELISA is the leading method segment in the market. Read more

Enzyme Linked Immunosorbent Assay Market, by Method (Direct ELISA, Indirect ELISA, Sandwich ELISA and Competitive ELISA), by Application (Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry & Transplantation), by Technology (Chemiluminescent, Colorimetric, & Fluorescent), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Jul 2022
CMI1505
170 Pages
Excel & Pdf
Clinical Diagnostic

Summary

Enzyme Linked Immunosorbent Assay (ELISA) is immunoassay used to identify proteins, peptides, antibodies, and hormones. ELISA assay has application in biotechnology medicine, as a diagnostic tool, which detects color change to identify a target substance and measures its concentration in the test sample. The common diagnostic applications of ELISA are Human Immunodeficiency Virus (HIV) infection, pregnancy tests, and measurement of cytokines, soluble proteins, and others. Various antigen-antibody combinations are used in the immunoassay that include an enzyme-labeled antigen or antibody and enzyme activity is measured.

Global Enzyme Linked Immunosorbent Assay (ELISA) Market is estimated to be valued at US$ 2,016.1 million in 2022 and is expected to exhibit a CAGR of 5.1% during the forecast period (2022-2030).

Figure 1. Global Enzyme Linked Immunosorbent Assay (ELISA) Market Share (%), by Method, 2022

Increasing product development activities for ELISA kit are expected to drive growth of the Global Enzyme Linked Immunosorbent Assay (Elisa) Market.

Increasing product development activities for ELISA kit are expected to drive growth of the global Enzyme Linked Immunosorbent Assay (ELISA) market. For instance, On May 21, 2021, The Defence Institute of Physiology and Allied Sciences (DIPAS), a laboratory of Defence Research and Development Organization (DRDO), India had developed an antibody detection-based kit 'DIPCOVAN', the DIPAS-VDx COVID-19 IgG Antibody Microwell ELISA for sero-surveillance. The DIPCOVAN kit can detect both spike as well as nucleocapsid proteins of SARS-CoV-2 virus with a high sensitivity of 97% and specificity of 99%. The kit had been developed in association with Vanguard Diagnostics Pvt Ltd, a diagnostics development and manufacturing company.

Enzyme Linked Immunosorbent Assay (ELISA) Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 2,016.1 Mn
Historical Data for:	2017 to 2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	5.1%	2030 Value Projection:	US$ 3,004.3 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Method: Direct ELISA, Indirect ELISA, Sandwich ELISA, Competitive ELISA By Application: Vaccine Development, Immunology, Diagnostics, Toxicology, Drug Monitoring & Pharmaceutical Industry, Transplantation By Technology: Chemiluminescent, Colorimetric, Fluorescent
Companies covered:	Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., R&D Systems, Creative Diagnostics, Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.
Growth Drivers:	Increasing product development activities for ELISA kit Increasing inorganic activities among market players
Restraints & Challenges:	Product recalls being ordered by regulatory authorities

Figure 2.Global Enzyme Linked Immunosorbent Assay (ELISA) Market Share (%), by Region, 2022

Increasing inorganic activities such as collaboration among market players is expected to drive market growth over the forecast period

Market players are focused towards expansion of their product portfolio and geographic reach by adoption of inorganic strategies such as collaboration to maintain their positions in market. For instance, on June 2, 2020, Syngene International Ltd., an integrated research and development services company, had entered into collaboration with HiMedia Laboratories, a bioscience company with expertise in media manufacturing and diagnostics for over 45 years, to manufacture and distribute its ELISA kits. HiMedia would manufacture the kits at its facility in Mumbai, India and distribute it across India.

Global Enzyme Linked Immunosorbent Assay (ELISA) Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.

The COVID-19 can affect the economy in three main ways: by directly affecting the production and demand of clinical diagnostic devices by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of clinical diagnostic devices from one place to another.

However, the COVID-19 pandemic had a positive impact on the global Enzyme Linked Immunosorbent Assay (ELISA) market, owing to increased Emergency Authorization by regulatory authorities for ELISA Kit for detection of COVID-19 infection. For instance, on January 8, 2021, The Central Drugs Standard Control Organization (CDSCO), India announced product approval for ELISA kit, which was indicated for detection of COVID-19 infection and manufactured by CPC Diagnostics Pvt. Ltd., a manufacturing company of Medical Laboratory Equipment, analyzer products.

Global Enzyme Linked Immunosorbent Assay (ELISA) Market: Key Development

On October 28, 2020, Cipla Limited, a pharmaceutical company had announced the commercialization of antibody detection kits for COVID-19 in India. In partnership with KARWA Ltd. a manufacturing and distributor company under the technology transfer from the Indian Council of Medical Research (ICMR). As part of this collaborative effort, Cipla would be responsible for the marketing and distribution of the SARS CoV-2-IgG antibody detection ELISA that will be manufactured by KARWA Ltd. ICMR has provided the requisite technological know-how and process for developing the test kits to the approved manufacturers.

Global Enzyme Linked Immunosorbent Assay (ELISA) Market: Restraint

Product recalls being ordered by regulatory authorities is expected to hamper growth of global Enzyme Linked Immunosorbent Assay (ELISA) market over forecast period. For instance, On December 01, 2020, The U.S. Food and Drug administration (FDA) issued a notice to recall the Class 2 Device Recall ACCEL ELISA COVID19 Test, which is indicated for the detection of total antibodies to SARS-CoV-2 and manufactured by VEO Diagnostics, a manufacturer of medical diagnostic products.

Key Players

Major players operating in the global Enzyme Linked Immunosorbent Assay (ELISA) market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., R&D Systems, Creative Diagnostics, Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.

Table of Content

Table of Contents

*Browse 34 market data tables and 38 figures on "Global Enzyme Linked Immunosorbent Assay (ELISA) Market” - forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global Enzyme Linked Immunosorbent Assay (ELISA) market during the forecast period (2022-2030)?

The global Enzyme Linked Immunosorbent Assay (ELISA) market size is estimated to be valued at US$ 2,016.1 million in 2022 and is expected to exhibit a CAGR of 5.1% between 2022 and 2030.

What are the major factors driving the market growth?

Increasing product development activities for ELISA kit and increasing inorganic activities among market players are major factors driving the market growth.

Which is the leading vaccine segment in the market?

Direct ELISA is the leading method segment in the market.

What are the key factors hampering growth of the market?

The major factors hampering growth of the market include product recalls being ordered by regulatory authorities

Which are the major players operating in the market?

Major players operating in the market include Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., Thermo Fisher Scientific, Inc., Biomerieux S.A., Alpco, BioLegand, Inc., R&D Systems, Creative Diagnostics, Zeus Scientific, Inc., and Shenzhen YHLO Biotech Co., Ltd.